Table 3: Comparison of presence of autoantibodies among CTD-ILD, UCTD-ILD, and IPF patients.

CTD-ILDUCTD-ILDIPFP1P2P3

Subject (n)636575
ANA n (%)45 (71)34 (52)16 (21)0.0260.0000.000
RF n (%)26 (42)9 (14)7 (9)0.0010.0000.403
Anti-ds-DNA n (%)000
RNP n (%)6 (10)000.0110.006
Anti-Smith n (%)2 (3)000.1480.102
Anti-SSA n (%)18 (28)0 00.0000.000
Anti-SSB n (%)5 (8)5 (8)00.9590.0110.014
Anti-Scl-70 n (%)4 (6)4 (6)00.9640.0270.029
ANCA n (%)000
ACA n (%)3 (5)000.0750.056
Anti-CCP n (%)8 (13)000.0030.001
Anti-Jo-1 n (%)2 (3)000.1480.120
AKA n (%)6 (3)000.0110.001

P1: Possibility when comparing CTD-ILD group and UCTD-ILD group. P2: Possibility when comparing CTD-ILD group and IPF group. P3: Possibility when comparing UCTD-ILD group and IPF group.